United European Gastroenterology Journal, First Published 20 Jun 2018.
C. Reenaers, P. Bossuyt, P. Hindryckx, H. Vanpoucke, A. Cremer, F. Baert; Belgian IBD Research and Development Group
Abstract
Background: Despite many publications regarding the role of faecal calprotectin (FC) in inflammatory bowel disease (IBD),
clear recommendations for its use in clinical practice are currently lacking in the literature.
Aim: The aim of this article is to provide practical guidance for clinicians for the use of FC in the detection and management
of patients with IBD.
Methods: All relevant publications were analysed and practical statements were proposed based on a Delphi consensus
approach.
Results: Different commercial assays have been developed but international standardisation is lacking. FC can help in the
diagnosis process of IBD. In IBD, FC can predict response to therapy, detect subclinical inflammation and help to drive
treatment decisions to achieve better endoscopic and clinical outcomes. After Crohn’s surgery FC can identify patients with
early endoscopic recurrence.
Conclusion: Although major therapeutic changes should not be based on FC alone, FC is a valuable tool to optimise the care
for IBD patients.
